Clinical trial
A Phase IIIb, Open-label, Multi-center Study to Evaluate the Immunogenicity and Safety of a Booster Dose and Describe the Immune Persistence of MenACYW Conjugate Vaccine With 5- and/or 10-year Booster Doses in Children and Adolescents Who Had Been Primed With MenACYW Conjugate Vaccine as Toddlers.
NCT04936685 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIIb, Open-label, Multi-center Study to Evaluate the Immunogenicity and Safety of a Booster Dose and Describe the Immune Persistence of MenACYW Conjugate Vaccine With 5- and/or 10-year Booster Doses in Children and Adolescents Who Had Been Primed With MenACYW Conjugate Vaccine as Toddlers.
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- August 23, 2022
- Completion date
- December 26, 2027
- Enrollment
- 209 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.
healthy volunteers, meningococcal immunisation